Ety Klinger - 18 Mar 2026 Form 3 Insider Report for MediWound Ltd. (MDWD)

Reporting relationship
Chief Medical Officer
Issuer ticker
MDWD
Reported as of
18 Mar 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
18 Mar 2026, 17:33:55 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Yaron Meyer, attorney-in-fact

Key filing fact

Ety Klinger filed Form 3 for MediWound Ltd. (MDWD) on 18 Mar 2026.

Key facts

  • This page summarizes Ety Klinger's Form 3 filing for MediWound Ltd. (MDWD).
  • 0 reported transactions and 8 derivative rows are listed below.
  • Accepted by SEC: 18 Mar 2026, 17:33.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002082972 Primary reporting owner

Klinger Ety

Relationship
Chief Medical Officer
Address
C/O MEDIWOUND LTD., 42 HAYARKON STREET, YAVNE, ISRAEL
Signature
/s/ Yaron Meyer, attorney-in-fact
Signature date
18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDWD holding

Ordinary shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,743
Date
18 Mar 2026
Ownership
Direct
MDWD holding

Ordinary shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,500
Date
18 Mar 2026
Ownership
Direct
Footnotes
F1
MDWD holding

Ordinary shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
2,828
Date
18 Mar 2026
Ownership
Direct
Footnotes
F2
MDWD holding

Ordinary shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,750
Date
18 Mar 2026
Ownership
Direct
Footnotes
F3
MDWD holding

Ordinary shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,800
Date
18 Mar 2026
Ownership
Direct
Footnotes
F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MDWD holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary shares
Underlying amount
3,571
Exercise price
$36.05
MDWD holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary shares
Underlying amount
5,491
Exercise price
$12.25
MDWD holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary shares
Underlying amount
3,323
Exercise price
$37.52
MDWD holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary shares
Underlying amount
11,076
Exercise price
$14.42
Footnotes
F5
MDWD holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary shares
Underlying amount
9,300
Exercise price
$13.32
Footnotes
F6
MDWD holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary shares
Underlying amount
22,626
Exercise price
$12.73
Footnotes
F7
MDWD holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary shares
Underlying amount
14,000
Exercise price
$18.54
Footnotes
F8
MDWD holding Derivative

Stock Option (right to buy ordinary shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary shares
Underlying amount
15,000
Exercise price
$17.60
Footnotes
F9
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 9 footnotes

Footnote F1

The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on February 15, 2023 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F2

The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F3

The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F4

The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F5

The options reported in this row were granted to the Reporting Person on May 16, 2022 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F6

The options reported in this row were granted to the Reporting Person on February 15, 2023 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F7

The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F8

The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

Footnote F9

The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .